London’s Cori Clinical raises €3.56 million to accelerate clinical trials and reduce delays
Cori Clinical, a London-based startup that acts as the intelligence layer to accelerate clinical trials, has closed a €3.56 million ($4 million) Seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd. The company plans to use this capital to expand delivery capacity; support team growth, including appointing Chief Clinical Officer […] The post London’s Cori…
London-based startup Cori Clinical has secured €3.56 million ($4 million) in Seed funding from Breega to expedite clinical trials and minimize delays. The round was led by Breega and joined by Enzo, Heartfelt, Together Ventures, and Bynd. Cori Clinical's platform aims to streamline clinical trial processes by consolidating intelligence and regulatory insights into a unified workspace.
Co-founder and CEO Jorn Jansen Schoonhoven explains that clinical trials often face delays due to scattered knowledge, disconnected teams, and siloed information. The new capital will be used to enhance Cori's delivery capacity, expand its team (including the appointment of Chief Clinical Officer Dr. Emma Ogburn from Lindus Health), and strengthen its regulatory and clinical intelligence within the platform.
By integrating external data sources, including clinical-trial registries and regulatory guidance, Cori Clinical helps teams identify risks, evaluate options, and align study design with operational requirements. This approach aims to reduce average trial setup costs by at least 33%. The startup is already collaborating with two of the top five enterprise Contract Research Organizations (CROs) worldwide and serves customers across the clinical development ecosystem, including Erasmus MC, a leading academic medical center in Rotterdam.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
